{"title":"[1型神经纤维瘤病：最新进展]","authors":"Laura Fertitta, Pierre Wolkenstein","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>NEUROFIBROMATOSIS TYPE 1: RECENT ADVANCES. Neurofibromatosis type 1 (NF1) has been the subject of extensive research over the past decade, conducted by both French and international research groups. This work has led to significant advancements in the diagnosis, screening, and management of individuals with NF1. Current and future projects offer hope for new therapies targeting neurofibromas, whether plexiform or cutaneous, and effective against their malignant transformation.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 3","pages":"321-324"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Neurofibromatosis type 1: recent advances].\",\"authors\":\"Laura Fertitta, Pierre Wolkenstein\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>NEUROFIBROMATOSIS TYPE 1: RECENT ADVANCES. Neurofibromatosis type 1 (NF1) has been the subject of extensive research over the past decade, conducted by both French and international research groups. This work has led to significant advancements in the diagnosis, screening, and management of individuals with NF1. Current and future projects offer hope for new therapies targeting neurofibromas, whether plexiform or cutaneous, and effective against their malignant transformation.</p>\",\"PeriodicalId\":94123,\"journal\":{\"name\":\"La Revue du praticien\",\"volume\":\"75 3\",\"pages\":\"321-324\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"La Revue du praticien\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
NEUROFIBROMATOSIS TYPE 1: RECENT ADVANCES. Neurofibromatosis type 1 (NF1) has been the subject of extensive research over the past decade, conducted by both French and international research groups. This work has led to significant advancements in the diagnosis, screening, and management of individuals with NF1. Current and future projects offer hope for new therapies targeting neurofibromas, whether plexiform or cutaneous, and effective against their malignant transformation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
